000 02967cam  2200469zi 4500
0019.910323
003CaOODSP
00520221107182119
006m     o  d f      
007cr cn|||||||||
008220414t20222022onca    o    f000 0 eng d
020 |a9780660431376|z0660431376
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH14-393/2022E-PDF
24500|aUnderstanding Canadians' awareness, knowledge, attitudes and behaviours related to antimicrobial use and antimicrobial resistance : |bfinal report / |cprepared for: The Pubic Health Agency of Canada.
24614|aFinal integrated report : |bunderstanding Canadians' awareness, knowledge, attitudes and behaviours related to antimicrobial use and antimicrobial resistance
264 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2022.
264 4|c©2022
300 |a1 online resource (161 pages) : |billustrations + |e1 executive summary (8 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |a"POR-028-19."
500 |a"March 31, 2022."
500 |aIssued also in HTML format.
500 |a"Contract # 6DO37-192672/001/CY."
500 |a"Supplier Name: The Strategic Counsel."
500 |aIncorrect ISBN (0660431376) printed in this publication.
500 |aIssued also in French under title: Sensibilisation, connaissances, attitudes et comportements des canadiennes et des canadiens liés à l'utilisation d'antimicrobiens et à la résistance aux antimicrobiens : rapport final.
520 |a"Antimicrobial resistance (AMR) is a growing public health threat in Canada and around the world. Left unchecked, AMR could cause a return to a pre-antibiotic era in which common infections could once again become incurable, with grave consequences to the health of Canadians"--Executive summary, page 2.
650 0|aAnti-infective agents industry|zCanada|xPublic opinion.
650 0|aPublic opinion|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
7102 |aPublic Health Agency of Canada, |eissuing body.
7102 |aStrategic Counsel (Firm), |econsultant.
77508|tSensibilisation, connaissances, attitudes et comportements des canadiennes et des canadiens liés à l'utilisation d'antimicrobiens et à la résistance aux antimicrobiens : |w(CaOODSP)9.910324
85640|qPDF|s5.12 MB|uhttps://publications.gc.ca/collections/collection_2022/sc-hc/H14-393-2022-eng.pdf|zFinal report
85640|qPDF|s687 KB|uhttps://publications.gc.ca/collections/collection_2022/sc-hc/H14-393-2022-1-eng.pdf|zExecutive summary
8564 |qHTML|sN/A|uhttps://epe.lac-bac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/health/2022/028-19-e/report-en.html|zFinal report
8564 |qHTML|sN/A|uhttps://epe.lac-bac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/health/2022/028-19-e/summary/executive-sum-en.html|zExecutive summary